Endonovo Therapeutics annual operating margin
2010
2011
2012
2014
2018
2019
2020
2021
2022
Endonovo Therapeutics Operating Margin Growth & History (ENDV)
Endonovo Therapeutics's operating margin was −2,411.69% for fiscal 2022.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −2,411.69% | +634.00 pp |
| 2021 | 2021-12-31 | −3,045.68% | −1289.19 pp |
| 2020 | 2020-12-31 | −1,756.49% | −528.41 pp |
| 2019 | 2019-12-31 | −1,228.08% | +3767.25 pp |
| 2018 | 2018-12-31 | −4,995.33% | +4062.26 pp |
| 2014 | 2014-12-31 | −9,057.59% | −3360.10 pp |
| 2012 | 2012-12-31 | −5,697.49% | −5487.75 pp |
| 2011 | 2011-12-31 | −209.74% | −57.42 pp |
| 2010 | 2010-12-31 | −152.32% | — |
Endonovo Therapeutics quarterly operating margin
Q1.12
Q2.12
Q3.12
Q4.12
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2023 | 2023-09-30 | −31,105.07% | −26572.42 pp |
| Q2 2023 | 2023-06-30 | −2,502.90% | +274227.72 pp |
| Q1 2023 | 2023-03-31 | −604.63% | +20682.05 pp |
| Q4 2022 | 2022-12-31 | −397.69% | +117891.55 pp |
| Q3 2022 | 2022-09-30 | −4,532.65% | +4353.82 pp |
| Q2 2022 | 2022-06-30 | −276,730.62% | −274848.26 pp |
| Q1 2022 | 2022-03-31 | −21,286.68% | −19585.85 pp |
| Q4 2021 | 2021-12-31 | −118,289.24% | −112341.75 pp |
| Q3 2021 | 2021-09-30 | −8,886.47% | −6518.29 pp |
| Q2 2021 | 2021-06-30 | −1,882.36% | −533.91 pp |
| Q1 2021 | 2021-03-31 | −1,700.83% | −725.57 pp |
| Q4 2020 | 2020-12-31 | −5,947.49% | −5455.72 pp |
| Q3 2020 | 2020-09-30 | −2,368.18% | +21.32 pp |
| Q2 2020 | 2020-06-30 | −1,348.45% | +205.56 pp |
| Q1 2020 | 2020-03-31 | −975.26% | +833.33 pp |
| Q4 2019 | 2019-12-31 | −491.77% | +1957.85 pp |
| Q3 2019 | 2019-09-30 | −2,389.50% | +2469.30 pp |
| Q2 2019 | 2019-06-30 | −1,554.01% | +4799.30 pp |
| Q1 2019 | 2019-03-31 | −1,808.59% | +16483.78 pp |
| Q4 2018 | 2018-12-31 | −2,449.61% | +23263.09 pp |
| Q3 2018 | 2018-09-30 | −4,858.80% | +10865.53 pp |
| Q2 2018 | 2018-06-30 | −6,353.31% | −3314.65 pp |
| Q1 2018 | 2018-03-31 | −18,292.37% | −13260.35 pp |
| Q2 2015 | 2015-06-30 | −25,712.71% | −22519.27 pp |
| Q1 2015 | 2015-03-31 | −15,724.34% | −11707.74 pp |
| Q3 2014 | 2014-09-30 | −3,038.67% | +2165.07 pp |
| Q2 2014 | 2014-06-30 | −5,032.02% | −141.87 pp |
| Q1 2014 | 2014-03-31 | −3,193.44% | +22242.36 pp |
| Q4 2012 | 2012-12-31 | −4,016.59% | — |
| Q3 2012 | 2012-09-30 | −5,203.74% | — |
| Q2 2012 | 2012-06-30 | −4,890.15% | — |
| Q1 2012 | 2012-03-31 | −25,435.80% | — |
Endonovo Therapeutics operating margin trends
Over the last five reported fiscal years, Endonovo Therapeutics's operating margin increased from −9,057.59% to −2,411.69%, a change of +6645.90 percentage points. The latest reported quarter, Q3 2023, shows −31,105.07%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics filings at SEC.gov ↗